BAY 87-2243 sensitzes hepatocellular carcinoma Hep3B cells to histone deacetylase inhibitors treatment via GSK-3β activation

YANG-LING LI1,2*, MING-JUN RAO1,3*, NING-YU ZHANG4, LIN-WEN WU5, NENG-MING LIN1,3 and CHONG ZHANG4

1Department of Clinical Pharmacology, Hangzhou First People’s Hospital, Zhejiang Chinese Medical University; 2Department of Clinical Pharmacology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006; 3Institute of Pharmacology, College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 311402; 4School of Medicine, Zhejiang University City College, Hangzhou, Zhejiang 310015; 5College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, P.R. China

Received October 2, 2018; Accepted March 12, 2019

DOI: 10.3892/etm.2019.7500

Abstract. Hepatocellular carcinoma (HCC) is associated with some of the highest cancer-associated mortality rates. Histone deacetylase (HDAC) inhibitors anti-HCC activities have been shown to promote Snail-induced metastasis. In the present study, it was shown that BAY 87-2243, a hypoxia-inducible transcription factor-1α inhibitor, could enhance the anti-HCC effects of HDAC inhibitors, including trichostatin A and vorinostat. In addition, BAY 87-2243 plus HDAC inhibitors exhibited synergistic cytotoxicity and induced significant cell death in Hep3B cells. Additionally, BAY 87-2243 combined with HDAC inhibitors-treated Hep3B cells formed fewer and smaller colonies as compared with either the control or single agent-treated cells. Furthermore, glycogen synthase kinase-3β might be involved in the enhanced cell death induced by BAY 87-2243 plus HDAC inhibitors. The present data also indicated that BAY 87-2243 combined with HDAC inhibitors could suppress the migration of Hep3B cells, and BAY 87-2243 could reverse the HDAC inhibitor-induced Snail activation in Hep3B cells. In conclusion, BAY 87-2243 combined with HDAC inhibitors might be an attractive chemotherapy strategy for HCC therapy.

Introduction

Hepatocellular carcinoma (HCC), one of the most deadly cancers worldwide, accounts for the majority of primary liver cancer cases (1). The overexpression of histone deacetylases (HDACs) plays an important role in almost all cancerous behaviors of HCC, including cancer initiation, progression and chemotherapy-resistance (2). A number of HDAC inhibitors, such as vorinostat and trichostatin A, have been tested to treat HCC both in preclinical models and clinical trials (3-5). HDAC inhibitors exert their anti-tumor activities by inducing cell cycle arrest, apoptosis, autophagy and differentiation (6). Furthermore, combining HDAC inhibitors with other agents has been identified as a potential approach to overcoming chemotherapeutic resistance (7,8).

Hypoxia activates genetic programs that facilitate HCC metastasis, proliferation, as well as chemotherapy and radiotherapy-resistance (9). Hypoxia-inducible transcription factor (HIF) is activated in HCC cells under hypoxic conditions, leading to angiogenesis and poor prognosis (10). BAY 87-2243 inhibits HIF-1α and HIF-2α protein accumulation under hypoxia, and BAY 87-2243 also suppresses the activity of mitochondrial complex I in non-small cell lung cancer (11). Furthermore, BAY 87-2243 significantly reduces tumor growth in BRAF mutant melanoma cancer cells by targeting mitochondrial complex I (12). BAY 87-2243 induces mitochondrial permeability transition pore opening, stimulates autophagosome formation and leads to the activation of necroptotic/ferroptotic cell death in melanoma cells (13). In addition, the reduction of tumor hypoxia by application of BAY-87-2243 before the beginning of fractionated radiotherapy can improve local tumor control (14).

The activation of HDAC and hypoxia are associated with cancer initiation, progression and chemoresistance in HCC cells (9,10). The current study aimed to investigate whether
blocking both HDAC and hypoxia can be efficient to treat HCC. Thus, the authors hypothesized that combining HIF-1α inhibitor with HDAC inhibitor could be a logical combination regimen to treat HCC.

## Materials and Methods

**Cell culture and reagents.** BAY 87-2243 (cat. no. S7309), CHIR-99021 (cat. no. S2924), vorinostat (cat. no. S1047) and trichostatin A (cat. no. S1045) were purchased from Selleck Chemicals. Hep3B cells were purchased from the Cell Bank of the Chinese Academy of Sciences. The cells were cultured in MEM medium containing 10% fetal bovine serum (PAN Biotech) at 37°C in a humidified atmosphere with 5% CO₂. Propidium iodide (PI; cat. no. 70-ZF-50-0001) solution was purchased from Multi-Sciences Biotech.

**Cell proliferation assays.** Hep3B cells were seeded into 96-well plates at a density of 4x10⁴ per well and were allowed to grow overnight at 37°C. The cells were incubated with BAY 87-2243 (2 or 4 µM) and/or HDAC inhibitors (0.2-4 µM) for 72 h at 37°C. Cell proliferation was detected by the SRB assay, as previously described [9]. Briefly, cells were fixed with 10% trichloroacetic acid solution at 4°C overnight. Subsequent to washing, 0.4% SRB solution (100 µl per well; Sigma-Aldrich) was added into each well. After 20 min staining at room temperature, wells were rinsed with 1% acetic acid to remove unbound dye and then left to air dry. Subsequently, 100 µl Tris-base lye (10 mM; NeoFROXX GmbH) was added, followed by 10-min oscillation. The absorbance was then recorded at 515 nm using a multiscan spectrum.

**Colony formation assay.** Hep3B cells were seeded onto 6-well plates at a density of 1,000 cells per well. After 14 days, cells were stained with 0.1% crystal violet solution for 30 min at 4°C and the colonies were imaged by a camera.

**Detection of cell death.** Hep3B cells were seeded into 6 well plates and incubated with BAY 87-2243 (10 µM; higher than the SRB assay using 96 well plates) and/or and/or HDAC inhibitors (0.25-2 µM), and PI staining was then used to detect cell death, as previously described [9]. Sub-G1 analysis following PI staining was used to detect apoptosis. Cells were harvested, washed with PBS three times and fixed with pre-cooled 70% ethanol at -20°C overnight. Cells were washed and resuspended in 500 µl PBS containing 50 µg/ml RNase at 37°C for 30 min. The cells were then stained with 5 µg PI at room temperature for 30 min. For each sample, 2x10⁴ cells were collected and analyzed using a FACS-Calibur cytometer and the data were analyzed using CellQuest Software (version 6.0; BD Biosciences).

**Western blot analysis.** Western blot analysis was performed as previously described [9]. Proteins were extracted with lysis buffer containing 150 mM NaCl, 50 mM Tris-HCl, 0.1% sodium dodecyl sulfate, 1 mM ethylenediaminetetraacetic acid, 0.5% deoxycholic acid, 1% NP-40, 2.0 µg/ml aprotinin, 1 mM phenylmethylsulfonfonylfluoride and 0.02% sodium azide (Beyotime Institute of Biotechnology). The lysates were centrifuged at 10,000 x g for 30 min at 4°C, then the concentrations of protein were determined by the BCA method using Enhanced BCA Protein Assay kit (Beyotime Institute of Biotechnology). Total proteins (40 µg/lane) were fractionated on 8-15% Tris-glycine gels, and then they were transferred to polyvinylidene fluoride membrane, blocked with 5% (w/v) Difco Skim milk (cat. no. 232100; BD Biosciences) in PBS at room temperature for 1 h and probed with the primary antibodies at 4°C overnight. The proteins were incubated and visualized with horseradish peroxidase-conjugated goat anti-mouse (cat. no. GAM007) and anti-rabbit (cat. no. GAM007) IgG secondary antibodies (MultiSciences) at a dilution of 1:5,000 for 1 h at room temperature. Finally, proteins were visualized using the enhanced chemiluminescence detection system (PerkinElmer). Anti-poly (ADP-ribose) polymerase (PARP; cat. no. sc-7150; 1:1,000), anti-AKT (cat. no. sc-135829; 1:500), anti-phospho-AKT (Ser-473; cat. no. sc-7985; 1:500) and anti-GAPDH (cat. no. sc-25778; 1:1,000) antibodies were obtained from Santa Cruz Biotechnology, Inc. Anti-phospho-glycogen synthase kinase (GSK)-3β (Ser-9; cat. no. 5558S; 1:500) and anti-snail antibodies (cat. no. 38798; 1:1,000) were purchased from Cell Signaling Technology, Inc. Anti-GSK3β antibody (cat. no. 610202; 1:1,000) was obtained from BD Biosciences.

**Wound healing assay.** Hep3B cells were seeded in 24-well plates and cultured until they reached 90% confluency. Confluent monolayer cells were gently scratched with a sterile pipette tip and then washed three times with PBS to clear cell debris and suspended cells. Fresh serum-free medium was added, and the cells were allowed to close the wound for 24 h under normal conditions at 37°C. Images of the wound in the same relative position were captured with a computer-assisted microscope (model, CKX41SF; Olympus Corporation).

**Statistical analysis.** One-way analysis of variance followed by Tukey post hoc test was used to examine the significance of differences among groups. The results were presented as the mean ± standard deviation from three independent experiments and P<0.05 was used to indicate a statistically significant difference.

## Results

**BAY 87-2243 enhances the HDAC inhibitor-induced anti-proliferative effect of Hep3B cells.** First, the morphological changes induced by the combined treatment of BAY 87-2243 and HDAC inhibitors was detected in Hep3B cells. Fig. 1A showed that a very large proportion of Hep3B cells treated with BAY 87-2243 plus HDAC inhibitors (trichostatin A or vorinostat) had dislodged from the dishes whereas the remaining adherent cells showed loss of adhesion, shrinkage and rounding, which are typical morphological changes associated with apoptosis (15). Furthermore, the results presented in Fig. 1B showed that BAY 87-2243 combined with HDAC inhibitors (trichostatin A or vorinostat) significantly decreased the proliferation ability of Hep3B cells following incubation for 72 h, as compared with single agent-treatment. To further confirm the enhanced antiproliferative effect of the combined treatment with BAY 87-2243 and HDAC inhibitors, whether the combination might inhibit colony formation in Hep3B cells or not, was determined next. It was found that BAY 87-2243 combined with HDAC inhibitors-treated Hep3B cells formed...
fewer and smaller colonies as compared with either the control or single agent-groups (P<0.0001; Fig. 2A and B). These results confirmed that BAY 87-2243 enhanced the HDAC inhibitor-induced antiproliferative effect in Hep3B cells.

**BAY 87-2243 enhances HDAC inhibitor-induced cell death in Hep3B cells.** To determine whether the enhanced antiproliferative effect of BAY 87-2243 plus HDAC inhibitors resulted from cell death, PI staining was used to detect the cell death in Hep3B cells treated with BAY 87-2243 and/or HDAC inhibitors. The rate of cell death in Hep3B cells treated with BAY 87-2243 and trichostatin A was 70.13%, and it was significantly higher than that in the BAY 87-2243 group (28.94%) and trichostatin A group only (24.39%) following treatment for 48 h (Fig. 3A; upper panel). Similarly, the combination treatment of BAY 87-2243 and vorinostat

---

**Figure 1.** BAY 87-2243 enhances the anti-proliferation effect of Hep3B cells induced by HDAC inhibitors. (A) Hep3B cells were plated in 6-well plates and treated with BAY 87-2243 and/or HDAC inhibitors at the indicated concentrations for 72 h, and cell morphological changes were observed. Scale bar, 20 µm. (B) Hep3B cells were plated in 96-well plates and incubated with the compounds for 72 h. SRB assay was used to detect the proliferation of Hep3B cells. ***P<0.001. HDAC, histone deacetylase.

**Figure 2.** BAY 87-2243 enhances the anti-proliferation effects of Hep3B cells induced by HDAC inhibitors in colony formation assay. (A) Hep3B cells were treated with BAY 87-2243 (4 µM) and/or HDAC inhibitors (Trichostatin A, 0.25 µM; Vorinostat, 0.4 µM) for 14 days. (B) BAY 87-2243 enhanced the anti-proliferation effects of Hep3B cells induced by HDAC inhibitors in colony formation assay. ***P<0.001. HDAC, histone deacetylase.
resulted in an increased apoptotic rate, as compared with single agent groups (Fig. 3A; lower panel). Therefore, BAY 87-2243 enhanced HDAC inhibitor-induced cell death in Hep3B cells (P<0.0001; Fig. 3B). Furthermore, the BAY 87-2243 plus HDAC inhibitor-induced enhanced apoptosis was accompanied by higher expression of the cleaved PARP, in Hep3B cells (Fig. 4A).

**BAY 87-2243 combined with HDAC inhibitors induces cell death via GSK3β activation.** The AKT/GSK-3β/Snail pathway has been shown to be involved in HCC metastasis by inducing epithelial-mesenchymal transition (EMT) (16,17). The transcription factor Snail, controls EMT by repressing the expressions of E-cadherin and other epithelial genes, and GSK-3β phosphorylates Snail inducing its degradation (18). The present data indicated that BAY 87-2243 plus HDAC inhibitors could markedly inhibit AKT, Snail and activate GSK-3β by suppressing phosphorylated GSK-3β (Ser-9; Fig. 4A). Furthermore, it was found that GSK-3β inhibitor CHIR-99021 could partially reverse the cell death induced by BAY 87-2243 plus HDAC inhibitors (Fig. 4B; P<0.001). Thus, the potential ability of BAY 87-2243 plus HDAC inhibitors to inhibit the AKT/GSK-3β/Snail pathway makes it an attractive chemotherapy strategy to hinder HCC metastasis, but this needs to be investigated further.

**BAY 87-2243 combined with HDAC inhibitors suppresses the migration of Hep3B cells.** As shown in Fig. 5, untreated Hep3B cells migrated within 24 h after wounding, whereas there was moderate inhibition of cell migration when the Hep3B cells were treated with BAY 87-2243 (10 µM) or Trichostatin A (0.25 µM). However, BAY 87-2243 plus Trichostatin A could significantly suppress the migration of Hep3B cells (P<0.001). Similarly, BAY 87-2243 plus Vorinostat could also significantly inhibit the migration of Hep3B cells.

**Discussion**

HCC is a metabolically heterogeneous cancer, and the use of glucose by HCC cells can influence their tumorigenicity (19). Therefore, increased glucose metabolism is important for the growth of HCC cells (20). In addition, the suppression of
HDACs inhibit glucose metabolism and HCC cell growth by restoring fructose-1,6-bisphosphatase activity (3). BAY 87-2243 inhibits cell proliferation with low efficacy under standard conditions, but high efficacy under glucose depletion.
a condition favoring mitochondrial generation as an energy source (11). In the present study, it was hypothesized that HDAC inhibitors might increase the anti-HCC efficacy of BAY 87-2243 in HCC cells. Indeed, the results demonstrated that BAY 87-2243 may suppress the proliferation of HCC cells, and BAY 87-2243 plus HDAC inhibitors (trichostatin A or vorinostat) could distinctly inhibit proliferation and induce cell death in Hep3B cells. Therefore, a combination chemotherapy regimen incorporating BAY 87-2243 and HDAC inhibitors may be an effective chemotherapy strategy for the treatment of HCC.

HIF-1α could be activated by hypoxia-independent mechanisms such as the PI3K/AKT/mTOR signaling pathway (21). In the present study, BAY 87-2243 as a HIF-1α inhibitor could decrease p-AKT (ser-473), indicating that HIF-1α suppression could also affect PI3K/AKT/mTOR signaling pathway. Furthermore, the present data also indicated that BAY 87-2243 plus HDAC inhibitors could suppress PI3K/AKT/mTOR signaling. In addition, the inactivation of GSK-3β plays an important role in mediating the improved glucose metabolism, and GSK-3β (Ser-9) phosphorylation reduces the activity of GSK-3β (22,23). In the present study, it was shown that BAY 87-2243 plus HDAC inhibitors could activate GSK-3β by suppressing phosphorylated GSK-3β (Ser-9). In addition, GSK-3β inhibitor CHIR-99021 successfully reversed the cell death induced by BAY 87-2243 plus HDAC inhibitors. These data indicated that BAY 87-2243 plus HDAC inhibitors might suppress glucose metabolism by activating GSK-3β in HCC cells.

The majority of HCC patients are diagnosed in advanced stages of the disease, and the poor survival in patients with HCC can be largely attributed to rapid intrahepatic recurrence due to cancer metastases (24). HDAC inhibitors, including trichostatin A and vorinostat, induce cell death but simultaneously augment cell migration and metastasis to ruin therapeutic efficacy via activating protein kinase C signaling (25). Furthermore, HDAC inhibitors are able to promote the expression of Snail, and trigger Snail-induced EMT which is critical for HDAC inhibitors-initiated invasion and metastasis (26). The findings of the present study highlighted that BAY 87-2243 could reverse the HDAC inhibitor-induced activation of Snail in HCC cells. Furthermore, the present data showed that BAY 87-2243 plus HDAC inhibitor could significantly suppress the migration of HCC cells, indicating that combining BAY 87-2243 with HDAC inhibitors appears to be an attractive option for the patients with metastatic HCC. However, further research is required to elucidate the anti-metastatic activity of BAY 87-2243 plus HDAC inhibitors in HCC.

In conclusion, the present data provided, to the best of our knowledge, the first evidence that BAY 87-2243 could enhance the anti-HCC effect of HDAC inhibitors through the AKT/GSK-3β/Snail signaling pathway (Fig. 6). It was also shown that BAY 87-2243 plus Vorinostat could inhibit the migration of Hep3B cells. BAY 87-2243 plus HDAC inhibitors might be an attractive chemotherapy strategy for HCC.

Acknowledgements

Not applicable.

Funding

The present study was supported by Zhejiang Province Medical Key Discipline Construction (grant no. 2018-2-03, 2018), National Natural Science Foundation of China (grant no. 81702887, 2017), Hangzhou Major Science and Technology Project (grant no. 20172016A01, 2017), Fund of Hangzhou Medical Key Discipline Construction (grant no. 2017-51-07, 2017), and Zhejiang Provincial Foundation of Natural Science (grant nos. LQ16H310004, 2017 and LY19H310004, 2019).

Availability of data and materials

The analyzed data sets generated during the study are available from the corresponding author on reasonable request.
Authors’ contributions

YL, MJR, NYZ and LWW performed the experiments. NML and CZ conceived and designed the study. CZ wrote the manuscript. All authors read and approved the manuscript.

Ethics approval and consent to participate

This article does not contain any studies with animal or human participants performed by any of the authors.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References